The third interview is with the head of the Sanofi device unit. Out of the three, the Sanofi guy seems to be the most obsessed with the cost of devices, when he should be more focused on the strategic benefit an innovative device brings to the table.... Amgen are gunna leave Sanofi in the dust with this attitude...
https://www.lifescienceleader.com/d...erm=&utm_term=PAGE&utm_campaign=120516-V1--3-
Add to My Watchlist
What is My Watchlist?